For example, there are some reports that the efficacy against psoriatic arthritis tends to be higher with TNFα and IL-17 antibodies than with IL-12/23 antibodies, and IL-17 antibodies tend to aggravate the efficacy for inflammatory diseases (IBDs) [53]. This evidence concerns the gene IL17A and psoriatic arthritis.